Home » Regions » Global News » Ipsen, Harvard Medical School to collaborate

Ipsen, Harvard Medical School to collaborate

Monday, July 15, 2013

Global pharmaceutical company Ipsen has initiated an R&D collaboration on novel engineered botulinum toxins with Harvard Medical School. Ipsen will fund Harvard research for at least three years to discover, evaluate and develop novel engineered recombinant botulinum toxins for the treatment of neurologic diseases.

The collaboration will combine Harvard’s discovery platform and botulinum toxins engineering experience with Ipsen’s drug discovery and pharmaceutical R&D history. Ipsen will have worldwide rights to any candidate recombinant toxin stemming from the collaboration. Ipsen will be responsible for the development and marketing of the new toxins and will make associated upfront milestone and royalty payments to Harvard.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!